We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

65 hedge funds and large institutions have $75.5M invested in Gyre Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,982% more call options, than puts

Call options by funds: $5.11M | Put options by funds: $84K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.79% less ownership

Funds ownership: 8.61% → 7.81% (-0.79%)

6% less funds holding

Funds holding: 69 → 65 (-4)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

14% less capital invested

Capital invested by funds: $87.7M → $75.5M (-$12.2M)

71% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 31

Holders
65
Holders Change
-4
Holders Change %
-5.8%
% of All Funds
1.14%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
9
Reduced
31
Closed
16
Calls
$5.11M
Puts
$84K
Net Calls
+$5.03M
Net Calls Change
+$3.22M

Top Buyers

1
O
OrbiMed
New York
+$2.6M
2
PVI
Pura Vida Investments
New York
+$1.63M
3
SM
Sabby Management
Florida
+$464K
4
Citadel Advisors
Citadel Advisors
Florida
+$287K
5
JGC
J. Goldman & Co
New York
+$267K

Top Sellers

1
SCM
Stonepine Capital Management
Oregon
-$1.94M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.79M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.68M
4
ACP
Acuta Capital Partners
California
-$1.4M
5
PHP
Parkman Healthcare Partners
Connecticut
-$1.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$367K -$23.7K -720 -6%
EWM
27
Essex Woodlands Management
Texas
$323K – – –
Morgan Stanley
28
Morgan Stanley
New York
$321K -$123K -3,737 -26%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$309K – – –
State Street
30
State Street
Massachusetts
$298K +$128K +3,893 +67%
JJ
31
Johnson & Johnson
New Jersey
$275K +$294K +8,927 New
Citadel Advisors
32
Citadel Advisors
Florida
$268K +$287K +8,721 New
JGC
33
J. Goldman & Co
New York
$250K +$267K +8,101 New
DC
34
Davenport & Co
Virginia
$244K -$43.9K -1,333 -14%
Two Sigma Investments
35
Two Sigma Investments
New York
$222K +$69.4K +2,108 +41%
HF
36
HRT Financial
New York
$221K -$158K -4,801 -40%
TAM
37
Tocqueville Asset Management
New York
$206K -$19.7K -600 -8%
RJFSA
38
Raymond James Financial Services Advisors
Florida
$205K -$987 -30 -0.4%
BFM
39
Boothbay Fund Management
New York
$189K -$90K -2,735 -31%
BDF
40
Black Diamond Financial
Maryland
$173K – – –
Renaissance Technologies
41
Renaissance Technologies
New York
$164K -$1.79M -54,455 -91%
Barclays
42
Barclays
United Kingdom
$139K +$954 +29 +0.6%
CL
43
CSS LLC
Illinois
$138K +$147K +4,473 New
HSBC Holdings
44
HSBC Holdings
United Kingdom
$134K – – –
JP Morgan Chase
45
JP Morgan Chase
New York
$128K -$236K -7,185 -63%
VF
46
Virtu Financial
New York
$120K +$128K +3,880 New
Bank of America
47
Bank of America
North Carolina
$107K -$22.1K -672 -16%
Squarepoint
48
Squarepoint
New York
$105K -$94.5K -2,871 -46%
PP
49
PDT Partners
New York
$89K +$42.8K +1,302 +83%
CCIA
50
Cherry Creek Investment Advisors
Colorado
$82K +$87.8K +2,667 New
1
2
3 4

GYRE Hedge Fund Activity: Q3 2021 in Review

65 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2021, worth a combined $75.5M — down 14% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GYRE and 14 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 9 added.

The largest buyer was OrbiMed, adding an estimated $2.6M. The largest seller was Stonepine Capital Management, cutting an estimated $1.94M.

  • 65 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2021, down from 69 in Q2 2021.
  • Funds reported $75.5M of Gyre Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
  • 14 funds opened new Gyre Therapeutics positions in Q3 2021 and 16 closed out, a net change of -2 holders.
  • The largest Gyre Therapeutics buyer in Q3 2021 was OrbiMed, an estimated $2.6M added.
  • The largest Gyre Therapeutics seller in Q3 2021 was Stonepine Capital Management, an estimated $1.94M sold.

Based on aggregated 13F filings for Q3 2021.